The Health Care Maze: How We Treat Our Elderly: One Man’s Journey
نویسندگان
چکیده
منابع مشابه
The Health Care Maze: How We Treat Our Elderly: One Man’s Journey
©2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http:// creativecommons.org/licenses/by-nc-nd/3.0 for details. M y 83-year-old father was totally independent, driving a stick-shift sports car, teaching computer classes, and sitting on his condo board. He wo...
متن کاملHow I Treat How we treat lower-risk myelodysplastic syndromes
Myelodysplastic syndromes (MDSs) are clonal stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, and by a high incidence of progression to acute myeloid leukemia (AML). The pathophysiology of MDS is a multistep process involving genetic changes detectable by conventional cytogenetic techniques or smaller anomalies detectable only by more sophisticated meth...
متن کاملHow I treat How I treat elderly patients with myeloma
The clinical approach to older patients with myeloma has to be modified to take into account comorbidities and the likelihood of higher treatment-related toxicity. Individualization of management and adequate supportive therapy are important to obtain the best response while minimizing adverse effects. Corticosteroids, novel agents, conventional cytotoxic agents, and high-dose chemotherapy with...
متن کاملHow I Treat How we treat higher-risk myelodysplastic syndromes
s. 2012;120(21):1696. 73. Itzykson R, Kosmider O, Cluzeau T, et al;Groupe Francophone des Myelodysplasies(GFM). Impact of TET2 mutations on responserate to azacitidine in myelodysplastic syndromesand low blast count acute myeloid leukemias.Leukemia. 2011;25(7):1147-1152. 74. Sekeres MA, List AF, Cuthbertson D, et al.Phase I combination trial of lenalidomide andazacit...
متن کاملHow we treat Waldenström's macroglobulinemia.
Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic lymphoma which produces monoclonal immunoglobulin M (IgM). Over the last decade, new treatment modalites have been developed for the management of this disorder. Our objective is to provide treatment recommendations for WM. A review of published reports was facilitated by a MEDLINE computer search and by a manual search of Index Medicu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Diabetes
سال: 2015
ISSN: 0891-8929,1945-4953
DOI: 10.2337/diaclin.33.1.2